Actively Recruiting
Evaluation of Subcutaneous VGA039 for Preventing Bleeding in Adolescents and Adults with Von Willebrand Disease
Led by Vega Therapeutics, Inc · Updated on 2026-09-14
60
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of subcutaneous VGA039 as a preventive treatment for bleeding in patients with von Willebrand Disease VWD of all types. This Phase 3, open-label, multicenter study aims to gather detailed information about bleeding episodes and treatments in this population, providing crucial data on managing VWD. The study is sponsored by Vega Therapeutics, Inc and includes adolescent and adult patients aged 12 to 75 years. Participants will first enter an observational period lasting at least 24 weeks, during which bleeding events and treatments are recorded without intervention. After this, eligible participants will receive subcutaneous VGA039 for approximately 49 weeks. During the treatment phase, bleeding incidents, treatment details, and adverse events will be closely monitored and documented. Throughout both study phases, participants will keep diaries to track the number, duration, location, and types of bleeds experienced, along with treatments used. Researchers will monitor safety by recording adverse events continuously. The main outcome measured is the incidence of bleeding events from 7 days after consent until 49 weeks after starting VGA039. This comprehensive follow-up ensures detailed evaluation of both the treatment effects and safety over nearly a year of active therapy.
CONDITIONS
Brief Title
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Research Team
C
Clinical Trials- Vega Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here